scholarly journals Identification and characterization of OGG1 mutations in patients with Alzheimer's disease

2007 ◽  
Vol 35 (8) ◽  
pp. 2759-2766 ◽  
Author(s):  
Guogen Mao ◽  
Xiaoyu Pan ◽  
Bei-Bei Zhu ◽  
Yanbin Zhang ◽  
Fenghua Yuan ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Identification And Characterization

O4-06-08: Identification and characterization of a novel APP mutation (E693Δ) in familial Alzheimer's disease

2008 ◽  
Vol 4 ◽  
pp. T198-T198
Author(s):  
Takami Tomiyama ◽  
Tetsu Nagata ◽  
Hiroshi Takuma ◽  
Hiroyuki Shimada ◽  
Rie Teraoka ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Familial Alzheimer’S Disease ◽  
Familial Alzheimer's Disease ◽  
Identification And Characterization

The Therapeutic Potential of Purinergic Receptors in Alzheimer’s Disease and Promising Therapeutic Modulators

2020 ◽  
Vol 20 ◽  
Author(s):  
Lili Pan ◽  
Yu Ma ◽  
Yunchun Li ◽  
Haoxing Wu ◽  
Rui Huang ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Purinergic Receptors ◽  
Therapeutic Potential ◽  
Purinergic Signaling ◽  
Memory Loss ◽  
Related Research ◽  
Central Nervous System Disorders ◽  
G Protein Coupled

Abstract:: Recent studies have proven that the purinergic signaling pathway plays a key role in neurotransmission and neuromodulation, and is involved in various neurodegenerative diseases and psychiatric disorders. With the characterization of the subtypes of receptors in purinergic signaling, i.e. the P1 (adenosine), P2X (ion channel) and P2Y (G protein-coupled), more attentions were paid to the pathophysiology and therapeutic potential of purinergic signaling in central nervous system disorders. Alzheimer’s disease (AD) is a progressive and deadly neurodegenerative disease that is characterized by memory loss, cognitive impairment and dementia. However, as drug development aimed to prevent or control AD follows a series of failures in recent years, more researchers focused on the neuroprotection-related mechanisms such as purinergic signaling in AD patients to find a potential cure. This article reviews the recent discoveries of purinergic signaling in AD, summaries the potential agents as modulators for the receptors of purinergic signaling in AD related research and treatments. Thus, our paper provided an insight for purinergic signaling in the development of anti-AD therapies.

scholarly journals Characterization of monomeric and soluble aggregated Aβ in Down’s syndrome and Alzheimer’s disease brains

2021 ◽  
Vol 754 ◽  
pp. 135894
Author(s):  
Eleni Gkanatsiou ◽  
Charlotte Sahlin ◽  
Erik Portelius ◽  
Malin Johannesson ◽  
Linda Söderberg ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Down's Syndrome ◽  
Down’S Syndrome

scholarly journals Single-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer’s disease

2021 ◽  
Author(s):  
Samuel Morabito ◽  
Emily Miyoshi ◽  
Neethu Michael ◽  
Saba Shahin ◽  
Alessandra Cadete Martini ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Chromatin Accessibility ◽  
Single Nucleus
Sign in / Sign up

Export Citation Format

Share Document